Kishorchandra Gonsai
Addiction Psychiatry · West Haven, CTNPI 1043308760
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 280 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 27.5% of the total. Reporting peaked in 2021 at $1,444 and has fallen 64.7% since, to $509 in 2025.
Across 280 payments — averaging $18.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$539
- Lundbeck LLC$328
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$310
- Eisai Inc.$246
- plus $1K from 14 others
What the payments were for
- Food & beverage$5,09499%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 95 | $1,409 |
| AbbVie | 50 | $1,109 |
| Otsuka America Pharmaceutical, Inc. | 27 | $539 |
| Lundbeck LLC | 16 | $328 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $310 |
| Eisai Inc. | 15 | $246 |
| Alkermes, Inc. | 14 | $240 |
| Sunovion Pharmaceuticals Inc. | 7 | $182 |
| Almatica Pharma LLC | 9 | $156 |
| Axsome Therapeutics, Inc. | 7 | $143 |
| Vanda Pharmaceuticals Inc. | 5 | $92 |
| Jazz Pharmaceuticals Inc. | 4 | $76 |
| Supernus Pharmaceuticals, Inc. | 4 | $68 |
| Neos Therapeutics, LP | 2 | $44 |
| Corium, LLC | 2 | $40 |
| Indivior Inc. | 2 | $39 |
| Neurocrine Biosciences, Inc. | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 1 | $30 |
| Bausch Health US, LLC | 1 | $20 |
| Tempus AI, Inc | 1 | $17 |
How this compares
Too few addiction psychiatry providers in Connecticutto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 70 | $9,922 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 79 | $2,388 |
| Trazodone Hcl | 54 | $958 |
| Clonazepam | 124 | $736 |
| Lorazepam | 52 | $612 |
| Lurasidone Hcl | 16 | $588 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 12 | $582 |
| Topiramate | 16 | $269 |
| Lamotrigine | 25 | $234 |
| Oxcarbazepine | 14 | $224 |
| Buspirone Hcl | 16 | $215 |
| Hydroxyzine Hcl | 18 | $175 |
| Bupropion XlBupropion Hcl | 12 | $169 |
| Quetiapine Fumarate | 28 | $141 |
| Duloxetine Hcl | 26 | $131 |
Paid to pharmacies, not to this prescriber.
Other addiction psychiatry in West Haven
- Ismene PetrakisWest Haven$16K
- Maria Garcia VassalloWest Haven$45
- Shelby PowersWest Haven$23
- Lynn WintherMiddletown$479
- Michael AduseiStamford$477
- Mahfuza AkhtarNorwich$257
- Zinaida BoutaevaOrange$253
- Jean JardaMiddletown$216
- Gengyun WenMansfield Center$198
- Harsha DuvviMiddletown$197
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.